Primary Nocturnal Enuresis
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Ferring PharmaceuticalsArgentina - Buenos Aires
2 programsdesmopressinPHASE_31 trial
MINIRIN Oral LyophilisatePHASE_41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsMINIRIN Oral Lyophilisate
Ferring Pharmaceuticalsdesmopressin
Clinical Trials (2)
Total enrollment: 353 patients across 2 trials
A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
Start: Dec 2004Est. completion: Sep 2005221 patients
Phase 4Completed
Desmopressin Response in the Young
Start: Jul 2004Est. completion: Feb 2006132 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.